RXRX
NasdaqRECURSION PHARMACEUTICALS, INC.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$10.2M
2021
$39.8M
2022
$44.6M
2023
$58.8M
2024
$74.7M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$74.7M
Net Income$-644.8M
Gross Profit—
Oper Income$-648.1M
EPS (dil)$-1.44
Rev/sh$0.44
FCF/sh$-2.25
Book/sh$6.72
Gross M—
Oper M-867.9%
Profit M-863.4%
FCF M-506.5%
ROE-57.0%
ROA-43.7%
ROIC-171.3%
R&D/Rev636.4%
Rev Y/Y26.9%
Rev 3Y CAGR23.3%
EPS Y/Y14.8%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+63.2%
Current Ratio5.50
Quick Ratio—
Debt/Eq0.00
Int Coverage-358.1×
Net Debt$753.2M cash
Total Debt$723,000
Cash & Eq$753.9M
Total Assets$1.5B
Oper CF$-371.8M
Capex$6.5M
Free CF$-378.3M
Buybacks—
Equity$1.1B
Liabilities$343.3M
Shs Outstand0.17B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-182.8M | $-245.7M | $-350.1M | $-479.0M | $-648.1M |
| Net Income | $-186.5M | $-239.5M | $-328.1M | $-463.7M | $-644.8M |
| Diluted EPS | $-1.49 | $-1.36 | $-1.58 | $-1.69 | $-1.44 |
| Operating Cash Flow | $-158.6M | $-83.5M | $-287.8M | $-359.2M | $-371.8M |
| Free Cash Flow | $-198.4M | $-120.6M | $-299.7M | $-372.9M | $-378.3M |
COMMUNITY · $RXRX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.